Global Efforts Intensify In Fight Against Counterfeit Drugs
Executive Summary
Regulators and manufacturers worldwide intensify cracking down on the scourge of counterfeit drugs, with APEC launching a toolkit, industry recruiting participants for a shared audit program and WHO warning that the problem is not going away anytime soon. While anti-malarials and -infectives and vaccines continue as prime targets, a new trend is emerging in “well-regulated’ markets of high-priced hepatitis drugs falsified.
You may also be interested in...
FDA, Industry Aim to Further Strengthen Pharma Supply Chain Quality
A stronger pharma supply chain is in the works. Key is to put quality on CEO's radar screen. Progress made in supplier auditing, supply chain standard-setting and regulatory guidance development. Methods shared for improving supplier management. Supply chain mapping recommended. A better certificate of analysis. A think tank for signal detection. Improving distribution security and controls. Support for track-and-trace reimbursement incentive.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.